1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,837 | 0,883 | 10:33 | |
| 0,837 | 0,883 | 10:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.03. | MIRA PHARMACEUTICALS, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 24.03. | What's Going On With MIRA Pharma Stock Tuesday? | 2 | Benzinga.com | ||
| 23.03. | MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies | 193 | ACCESS Newswire | Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain MIAMI, FL / ACCESS... ► Artikel lesen | |
| MIRA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.03. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 4 | SEC Filings | ||
| 04.03. | MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 | 2.013 | ACCESS Newswire | Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS... ► Artikel lesen | |
| 03.03. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 03.02. | MIRA Pharmaceuticals initiates final dosing in phase 1 trial of Ketamir-2 | 2 | Investing.com | ||
| 03.02. | MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study | 371 | ACCESS Newswire | Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026... ► Artikel lesen | |
| 02.02. | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.12.25 | Mira Pharmaceuticals genehmigt CEO-Boni inklusive Prämie für SKNY-Akquisition | 4 | Investing.com Deutsch | ||
| 20.12.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.12.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.11.25 | RECIPHARM AB: Telomir and Mira Pharmaceuticals advance through key development milestones with Recipharm support | 2 | Cision News | ||
| 13.11.25 | MIRA PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.25 | MIRA Pharmaceuticals Initiates Multiple Ascending Dose Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication | 410 | ACCESS Newswire | Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire /... ► Artikel lesen | |
| 23.10.25 | MIRA PHARMACEUTICALS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 16.10.25 | Mira Pharmaceuticals stock soars after positive pain treatment study results | 12 | Investing.com | ||
| 16.10.25 | Morning Market Movers: rYojbaba, Linkage Global, MIRA Pharmaceuticals, Fossil Group See Big Swings | 801 | AFX News | LOWELL (dpa-AFX) - At 7:45 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 16.10.25 | MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain | 421 | ACCESS Newswire | Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA... ► Artikel lesen | |
| 16.10.25 | Why Mira Pharmaceuticals Shares Rose 69% After Hours? | 24 | Benzinga.com |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,55 | +0,36 % | Biotech-Werte im Check: Warum Bioxyne, Newron und BioNTech jetzt auf Substanz statt Hoffnung setzen | ||
| EVOTEC | 4,984 | +6,04 % | EQS-News: Evotec SE: Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden | EQS-News: Evotec SE
/ Schlagwort(e): Personalie
Evotec nominiert Dieter Weinand als Aufsichtsratsvorsitzenden
07.04.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| BB BIOTECH | 49,700 | -2,17 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| QIAGEN | 35,820 | +1,33 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| AMGEN | 296,95 | -0,17 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| NOVAVAX | 6,960 | +1,02 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 296,20 | +0,30 % | Stryker To Buy Amplitude Vascular Systems | WASHINGTON (dpa-AFX) - Stryker Corporation (SYK), a medical technology company, said on Monday that it has signed a deal to buy Amplitude Vascular Systems, Inc., a privately held developer of... ► Artikel lesen | |
| BIOGEN | 151,80 | +1,17 % | Biogen to acquire Apellis in $5.6bn deal | ||
| ILLUMINA | 108,42 | +0,44 % | Illumina Expands Collaboration With Labcorp To Advance Precision Oncology | SAN DIEGO (dpa-AFX) - Illumina, Inc. (ILMN), Wednesday announced an expanded collaboration with Labcorp to advance precision oncology through innovative applications of next-generation sequencing... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,315 | +1,52 % | 2 Billion Reasons to Love CRISPR Therapeutics Right Now | ||
| AAP IMPLANTATE | 1,400 | 0,00 % | AAP Implantate AG zeigt strukturelle Stärke | ||
| OCUGEN | 1,536 | +1,19 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,886 | -4,83 % | What's Going On With Inovio Pharmaceuticals Stock On Tuesday? | ||
| SANGAMO THERAPEUTICS | 0,223 | +0,27 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results | Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across... ► Artikel lesen | |
| VIKING THERAPEUTICS | 30,000 | +0,67 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen |
Das Unternehmen MIRA PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,012 (-1,33 %) liegt der Kurs bei 0,852 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MIRA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.